Lupenox 40mg Injection contains Enoxaparin sodium, a low molecular weight heparin (LMWH) used as an anticoagulant to prevent and treat thromboembolic disorders. It acts by inhibiting factor Xa and IIa (thrombin), thereby reducing the formation of fibrin clots. Lupenox is indicated for the prophylaxis of deep vein thrombosis (DVT) in patients undergoing surgery or those immobilized due to acute illness, as well as for the treatment of established DVT with or without pulmonary embolism. It is also utilized in the management of unstable angina and non-ST elevation myocardial infarction (NSTEMI) to reduce the risk of further ischemic complications. Administered via subcutaneous injection, Lupenox offers predictable anticoagulant effects with a more favorable safety profile compared to unfractionated heparin, including a lower risk of heparin-induced thrombocytopenia. Dosage and duration of therapy should be individualized based on patient weight, renal function, and clinical indication. Monitoring of anti-factor Xa levels may be necessary in special populations such as those with renal impairment or obesity. Caution is advised in patients with bleeding disorders, active bleeding, or hypersensitivity to enoxaparin or heparin. Lupenox should be used under medical supervision with appropriate monitoring to minimize adverse effects.